Collegium Pharmaceutical Inc

Research Collegium Pharmaceutical Inc (COLL) on Bullrun: valuation model: 4.8% undervalued, market cap USD 1.17B, P/E 17.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCOLL
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Valuation signal4.8% undervalued
• Market capUSD 1.17B
• P/E17.6
• Financial periodFY2025
• RevenueUSD 780.57M
• Revenue growth23.6%
• Net incomeUSD 63.00M
• Free cash flowUSD 327.58M
• Gross margin59.3%

Valuation Snapshot

Bullrun's latest valuation model marks Collegium Pharmaceutical Inc as 4.8% undervalued; latest market cap is USD 1.17B; P/E is 17.6.

About Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period;

Frequently asked questions

Is Collegium Pharmaceutical Inc overvalued or undervalued?

Bullrun's valuation model currently marks Collegium Pharmaceutical Inc as 4.8% undervalued.

What is Collegium Pharmaceutical Inc's market cap?

Collegium Pharmaceutical Inc's market capitalization is USD 1.17B.

What is Collegium Pharmaceutical Inc's P/E ratio?

Collegium Pharmaceutical Inc's price-to-earnings (P/E) ratio is 17.6.

What does Collegium Pharmaceutical Inc do?

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.